Significance of Immunohistochemical Expression of Fascin-1 in Colorectal Carcinoma

• Sponsor: Sohag University (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT05553080
• Collaborator: (none)
• Enrollment: 60
• Locations: 2
• Anticipated Duration (Months): 11
• Patients Per Site: 30
• Patients Per Site Per Month: 2.7

Study Details

Study Description

Brief Summary

Colorectal carcinoma is a major health problem. As a malignant tumor, the malignant potential of colorectal carcinoma is based mainly on its ability to metastasis to different sites. Fascin-1 is an actin binding protein which is involved in reconstruction of intracellular actin network, the latter enforces the neoplastic cell to invade surrounding structures.

Condition or Disease	Intervention/Treatment	Phase
Cancer of Colon	Genetic: Immunohistochemistry

Detailed Description

colorectal carcinoma is an aggressive malignant tumor. It has high incidence of cancer-related morbidity and mortality. the malignant potential of a given neoplasm is based mainly on its ability to invade the surrounding vasculature and reach to distant sites, the latter is called metastasis. in order to metastasize to distant sites, the neoplastic cells must re-arrange the intracellular actin filaments into well formed intracellular assembly which enable the neoplastic cells to reach to distant sites. Fascin-1 is an actin binding protein, it is involved in reconstruction of actin assembly. fortunately, Fascin-1 could be blocked by newly developed medications, blocking of Fascin-1 may limit the metastasis of colorectal carcinoma. in current study the investigators detect Fascin-1 in colorectal carcinoma by immunohistochemical approach, then they correlated different levels of Fascin-1 expression to tumor clinical and pathological criteria as patients' ages, sexes, tumor stages, nodal metastasis, vascular and per-ineural invasions.

Study Design

• Study Type: Observational
• Anticipated Enrollment: 60 participants
• Observational Model: Case-Only
• Time Perspective: Prospective
• Official Title: Significance of Immunohistochemical Expression of Fascin-1 in Colorectal Carcinoma
• Actual Study Start Date: Jan 1, 2022
• Actual Primary Completion Date: Sep 30, 2022
• Anticipated Study Completion Date: Dec 1, 2022

Outcome Measures

Primary Outcome Measures

1. Evaluation of immunohistochemical staining of colorectal carcinoma by Fascin-1 [September , 2022]

   correlation of different levels of Fascin-1 expression to patients' ages, sexes, tumor stage, nodal metastasis, vascular and perineural invasion.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 30 Years to 90 Years
• Sexes Eligible for Study: All

Inclusion Criteria:

• All cases of colorectal carcinoma.

Exclusion Criteria:

• cases diagnosed on basis of lower endoscopic biopsies or local resections without radical colectomy.

• Patients with preopoerative history of chemo or radiotherapy.

• Patients with poor clinical data.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Maisa Hashem Mohammed	Sohag		Egypt	82524
2	Sohag faculty of medicine	Sohag		Egypt	82524

Sponsors and Collaborators

• Sohag University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Maisa Hashem Mohammed, Lecturer of Pathology, Sohag University
• ClinicalTrials.gov Identifier: NCT05553080
• Other Study ID Numbers: Soh-Med-22-09-14
• First Posted: Sep 23, 2022
• Last Update Posted: Nov 1, 2022
• Last Verified: Oct 1, 2022

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Maisa Hashem Mohammed, Lecturer of Pathology, Sohag University: Cancer Colon; Fascin-1; Actin assembly
• Additional relevant MeSH terms: Colorectal Neoplasms; Colonic Neoplasms

Study Results

No Results Posted as of Nov 1, 2022